Dhaundiyal, AnkitKumari, PujaJawalekar, Snehal SainathChauhan, GauravKalra, SouravNavik, Umashanker2024-01-212024-08-142024-01-212024-08-142020-10-2824320510.1016/j.lfs.2020.118676http://10.2.3.109/handle/32116/4283Angiotensin-converting enzyme 2 (ACE 2) is a membrane-bound enzyme that cleaves angiotensin II (Ang II) into angiotensin (1�7). It also serves as an important binding site for SARS-CoV-2, thereby, facilitating viral entry into target host cells. ACE 2 is abundantly present in the intestine, kidney, heart, lungs, and fetal tissues. Fetal ACE 2 is involved in myocardium growth, lungs and brain development. ACE 2 is highly expressed in pregnant women to compensate preeclampsia by modulating angiotensin (1�7) which binds to the Mas receptor, having vasodilator action and maintain fluid homeostasis. There are reports available on Zika, H1N1 and SARS-CoV where these viruses have shown to produce fetal defects but very little is known about SARS-CoV-2 involvement in pregnancy, but it might have the potential to interact with fetal ACE 2 and enhance COVID-19 transmission to the fetus, leading to fetal morbidity and mortality. This review sheds light on a path of SARS-CoV-2 transmission risk in pregnancy and its possible link with fetal ACE 2. � 2020 Elsevier Inc.en-USACE 2Pregnancy and fetal transmissionSARS-CoV-2Reviewhttps://linkinghub.elsevier.com/retrieve/pii/S0024320520314296